Digestive & Liver Disease Specialists

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis

Nicholas C. Boetticher, Craig J. Peine, Paul Y. Kwo et al. · Gastroenterology · 2008 · 332 citations

Medicine, Internal Medicine, Pharmacology +8

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 186 citations

Medicine, Pharmacology, Pharmacotherapy +12

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

Stanislas Pol, Reem Ghalib, Vinod K. Rustgi et al. · The Lancet Infectious Diseases · 2012 · 147 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12